SeekingAlpha · Sep 23, 2026
Regencell Bioscience: I Got It Wrong (Rating Downgrade)
Regencell Bioscience is downgraded to hold amid $500M ATM risk, DOJ overhang, and key support break. Click here to read an analysis of RGC stock now.
RG
NASDAQ · RGC
Regencell Bioscience Holdings Limited
Healthcare · Drug Manufacturers - Specialty & Generic
$7.24
Up+$0.42 (+6.16%)
Updated Oct 6, 2026, 7:39 AM
SID Score
4.5/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 8.33B
- P/E ratio
- -2,324.68
- Dividend yield
- 0.00%
- 52-week range
- $4.51 – $69.00
- Volume
- 307.53K
- Avg. volume
- 194.68K
Price performance · RGC
RGC price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
RGC closed at $7.24 after 20 trading sessions, up 6.16% for the selected period.
- Last close
- $7.24
- Period change
- +6.16%
- Period low
- $5.60
- Period high
- $7.24
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $6.72 | $7.40 | $6.46 | $7.24 | 307.53K |
| Oct 2, 2026 | $6.37 | $7.39 | $6.22 | $6.82 | 429.4K |
| Oct 1, 2026 | $6.30 | $6.43 | $6.12 | $6.33 | 67.93K |
| Sep 30, 2026 | $6.24 | $6.25 | $6.1352 | $6.22 | 56.13K |
| Sep 29, 2026 | $6.11 | $6.2975 | $6.07 | $6.20 | 54.57K |
| Sep 28, 2026 | $6.15 | $6.30 | $6.05 | $6.20 | 76.16K |
| Sep 25, 2026 | $6.25 | $6.25 | $6.055 | $6.17 | 51.95K |
| Sep 24, 2026 | $6.08 | $6.26 | $5.91 | $6.17 | 91.49K |
| Sep 23, 2026 | $6.14 | $6.16 | $5.9221 | $5.98 | 134.46K |
| Sep 22, 2026 | $5.90 | $6.40 | $5.8607 | $6.23 | 126.39K |
| Sep 21, 2026 | $5.74 | $6.05 | $5.66 | $5.92 | 113.56K |
| Sep 18, 2026 | $6.00 | $6.10 | $5.75 | $5.79 | 94.3K |
| Sep 17, 2026 | $5.75 | $5.975 | $5.60 | $5.96 | 73K |
| Sep 16, 2026 | $5.62 | $5.73 | $5.48 | $5.68 | 128K |
| Sep 15, 2026 | $5.77 | $5.77 | $5.49 | $5.60 | 71.95K |
| Sep 14, 2026 | $5.63 | $5.84 | $5.63 | $5.74 | 73.03K |
| Sep 11, 2026 | $5.84 | $5.84 | $5.55 | $5.64 | 102.33K |
| Sep 10, 2026 | $5.95 | $6.20 | $5.5617 | $5.635 | 203.56K |
| Sep 9, 2026 | $6.72 | $6.7425 | $5.72 | $5.85 | 292.58K |
| Sep 8, 2026 | $6.91 | $7.1371 | $6.42 | $6.82 | 316.68K |
Latest RGC news
The latest Smart Investors Daily articles mentioning RGC.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RGC research
Overview
Company profile and research snapshot.
Company profile
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Jul 8, 2026
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics (NASDAQ:TVRD)
ChartMill · Jul 6, 2026
Unusual volume stocks are being observed in Monday's session.
Unusual volume stocks are being observed in Monday's session.
SeekingAlpha · Jul 6, 2026
United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises
Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
